Ghasemi Afsane, Amjadi Fatemehsadat, Masoumeh Ghazi Mirsaeed Seyedeh, Mohammad Beigi Robabeh, Ghasemi Samaneh, Moradi Yousef, Tahereh Ghazi Mirsaeed Seyedeh
Shahid Akbar Abadi Hospital Clinical Research Development Unit (ShACRDU), Iran University of Medical Sciences (IUMS), Tehran, Iran.
Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Int J Reprod Biomed. 2019 Nov 7;17(10):749-756. doi: 10.18502/ijrm.v17i10.5296. eCollection 2019 Oct.
In about 40% of the couples, the cause of infertility problems is attributed to men because of low sperm production and disturbed motility of sperm. Pieces of evidence show that Myo-inositol has a potential role for the treatment of sperm morphology and male fertility.
This study aimed to determine the effect of Myo-inositol on the sperm parameters and fertility rate in patients with oligoasthenospermia treated by intrauterine insemination (IUI).
This study was a randomized clinical trial conducted on 37 patients with oligoasthenospermia treated by IUI during 2016-2017. In this study, the patients were randomly divided into two groups of oligoasthenospermia treated with (Case group) and without Myo-inositol (Control group). The case group received 0.5 ml of Myo-inositol with a concentration of 2 mg/ml and incubated at 37°C incubator for 2 hr, but the control group had no interventions.
The results of this study showed that although there was no significant difference in sperm parameters including sperm motility and concentration before processing with Myo-inositol in the case group, but there was a significant increase in sperm motility during the treatment with Myo-inositol. The therapeutic effect of this method was confirmed on induction of pregnancy in 18% of the treated patients, in such a way that was about twice greater than those who did not receive the drug.
According to the results of this study, the use of Myo-inositol is efficient enough to change sperm parameters to increase the chance of fertility.
在约40%的夫妇中,不孕问题的原因可归因于男性,因为精子生成量低且精子活力紊乱。有证据表明,肌醇在治疗精子形态和男性生育能力方面具有潜在作用。
本研究旨在确定肌醇对接受宫腔内人工授精(IUI)治疗的少弱精子症患者精子参数和生育率的影响。
本研究是一项随机临床试验,对2016 - 2017年期间接受IUI治疗的37例少弱精子症患者进行。在本研究中,患者被随机分为两组,一组为接受肌醇治疗的少弱精子症患者(病例组),另一组为未接受肌醇治疗的患者(对照组)。病例组接受0.5毫升浓度为2毫克/毫升的肌醇,并在37°C培养箱中孵育2小时,而对照组未进行干预。
本研究结果表明,虽然病例组在使用肌醇处理前精子参数(包括精子活力和浓度)没有显著差异,但在使用肌醇治疗期间精子活力有显著提高。该方法对18%的治疗患者诱导妊娠的治疗效果得到证实,其效果约为未接受该药物治疗患者的两倍。
根据本研究结果,使用肌醇足以有效改变精子参数,增加生育机会。